||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 496 active entries
P.O.Box 4071, Weizmann Scientific Park
Ness Ziona 70400, Israel
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
QBI Enterprises Ltd. is a subsidiary of the California-based Quark Biotech Inc. (together herein “QBI”), serving as the incorporation’s main research center.
QBI is a pioneer in a new generation of applied genomics-based pharmaceutical companies. We are engaged in the discovery and development of therapeutic and diagnostic products that treat diseases by correcting their causes rather than just affecting their symptoms. Our drug discovery platform directly addresses the molecular mechanisms underlying disease. It comprises an integrative panel of high throughput technology including: microarray (chip) technologies, phenotype-specific functional profiling, proteomics and novel proprietary bioinformatics algorithms; validation technologies including transgenic and knock-out mice; proprietary bioassays for high throughput screens for small molecules as well as screening of chemical libraries and pre-clinical and clinical development.
We concentrate on those disease areas where current therapeutic alternatives are of limited efficacy or are non-existent and which have significant, large market opportunities such as cancer, cardiovascular diseases, stroke, osteoporosis and diabetes.
QBI has formed research alliances and collaborations with various pharmaceutical and life science partners in different disease research areas.
We have several potential products in advanced stages of development and we expect several potential products in our pipeline to commence clinical studies over the next five years.
Last update of this entry: October 19, 2000